» Articles » PMID: 26391748

Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician

Overview
Journal Am J Med
Specialty General Medicine
Date 2015 Sep 23
PMID 26391748
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

A panel of internists and nephrologists developed this practical approach for the Kidney Disease Outcomes Quality Initiative to guide assessment and care of chronic kidney disease (CKD) by primary care clinicians. Chronic kidney disease is defined as a glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) and/or markers of kidney damage for at least 3 months. In clinical practice the most common tests for CKD include GFR estimated from the serum creatinine concentration (eGFR) and albuminuria from the urinary albumin-to-creatinine ratio. Assessment of eGFR and albuminuria should be performed for persons with diabetes and/or hypertension but is not recommended for the general population. Management of CKD includes reducing the patient's risk of CKD progression and risk of associated complications, such as acute kidney injury and cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder. Prevention of CKD progression requires blood pressure <140/90 mm Hg, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglobin A1c ≤7% for patients with diabetes, and correction of CKD-associated metabolic acidosis. To reduce patient safety hazards from medications, the level of eGFR should be considered when prescribing, and nephrotoxins should be avoided, such as nonsteroidal anti-inflammatory drugs. The main reasons to refer to nephrology specialists are eGFR <30 mL/min/1.73 m(2), severe albuminuria, and acute kidney injury. The ultimate goal of CKD management is to prevent disease progression, minimize complications, and promote quality of life.

Citing Articles

Predicting Time in Range Without Hypoglycaemia Using a Risk Calculator for Intermittently Scanned CGM in Type 1 Diabetes.

Sebastian-Valles F, Arranz Martin J, Martinez-Alfonso J, Jimenez-Diaz J, Hernando Alday I, Navas-Moreno V Endocrinol Diabetes Metab. 2024; 8(1):e70020.

PMID: 39718005 PMC: 11667215. DOI: 10.1002/edm2.70020.


Assessing the quality of CKD care using process quality indicators: A scoping review.

Zhou N, Chen C, Liu Y, Yu Z, Bello A, Chen Y PLoS One. 2024; 19(12):e0309973.

PMID: 39656690 PMC: 11630614. DOI: 10.1371/journal.pone.0309973.


11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S239-S251.

PMID: 39651975 PMC: 11635029. DOI: 10.2337/dc25-S011.


Immune Microenvironment Alterations and Identification of Key Diagnostic Biomarkers in Chronic Kidney Disease Using Integrated Bioinformatics and Machine Learning.

Shi J, Xu A, Huang L, Liu S, Wu B, Zhang Z Pharmgenomics Pers Med. 2024; 17:497-510.

PMID: 39588536 PMC: 11586269. DOI: 10.2147/PGPM.S488143.


Proteinuria Assessment and Therapeutic Implementation in Chronic Kidney Disease Patients-A Clinical Audit on KDIGO ("Kidney Disease: Improving Global Outcomes") Guidelines.

Adelakun G, Boesing M, Mbata M, Pasha Z, Luthi-Corridori G, Jaun F J Clin Med. 2024; 13(17).

PMID: 39274550 PMC: 11395944. DOI: 10.3390/jcm13175335.